In Hong Kong, there are no explicit legal restrictions on the nationality or place of residence of shareholders in a company holding a pharmaceutical licence. As an international business centre, Hong Kong welcomes investors from around the world. However, when a shareholding change is notified, the regulatory authorities will still assess whether new major shareholders, particularly those able to exercise controlling influence over the company, are fit and proper. If a new shareholder is from a country or region subject to sanctions by an international organisation such as the United Nations, or has a poor international commercial or legal record, this may raise concerns and lead to more in-depth scrutiny by the regulatory authorities.
HONG KONG DRUG LICENSING
Will the nationality or place of residence of a new shareholder affect the licence when there is a shareholding change?
A complete explanation of the regulatory basis, Drew Tang’s recommendations and risk alerts. The original material dates from 2025; read it alongside the latest official requirements.
Original guide, 2025 edition: These FAQs are provided for topic-based reference and have not all been individually checked against current rules. Please confirm fees, personnel, renewal, changes and product requirements against the professional in-depth guide for the relevant licence type and the official requirements in force at the time.
Back to Category I: Renewals, Changes and Penalties for Breaches (Q401-Q450) Search more questions